Serum adipokines in inflammatory bowel disease

Table 1 Subject characteristics

	Crohn’s disease (n = 24)	Ulcerative colitis (n = 16)	Control group (n = 16)	P value
Female, %	54	56	50	0.902
Age, yr	31.0 ± 9.4	33.2 ± 21.9	30.3 ± 12.2	0.060
BMI, kg/m2	21.4 ± 2.8	23.4 ± 5.6	22 ± 4.8	0.444
Waist circumference, cm	78.8 ± 9.9	78.4 ± 15.7	78.5 ± 8.5	0.090
Hip circumference, cm	91.5 ± 8.8	93.6 ± 11.9	91.1 ± 8.1	0.345
Waist/hip ratio	0.86 ± 0.08	0.84 ± 0.08	0.86 ± 0.07	0.472
Duration of IBD, yr	9.5 ± 7.9	10.5 ± 8.1	-	0.105
Activity of IBD			-
CDAI	A: 241 ± 155	-
	B: 36.6 ± 25.3
Montreal severity classification
S0/S1/S2/S3	-	A: 0/1/14/1
		B: 8/8/0/0
Vienna classification		-	-
A1/A2	21/3
L1/L2/L3/L4	2/5/17/0
B1/B2/B3	14/6/4

A: Before treatment; B: 3 mo after initiation of treatment; CDAI: Crohn’s disease activity index; IBD: Inflammatory bowel disease; BMI: Body mass index.